North America remains a dominant regional hub for neurological biomarker development and commercialization due to its robust healthcare ecosystem, strong research capabilities, and increasing focus on early disease detection. The region benefits from extensive collaborations among academic institutions, research organizations, healthcare providers, and industry participants working to advance...